Tag: Nucala

March 15, 2017 Off

Severe asthma market is driving Nucala sales, opportunity for Teva, AstraZeneca, Sanofi, and Regeneron

Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.

March 6, 2017 Off

GSK study: Nucala improves patients with severe asthma health

By Dino Mustafić

Patients with eosinophilic inflammation that were treated with GSK’s mepolizumab Nucala as addition to the standard care, reached improvements in health and lung function compared to patients treated with placebo added to the standard care.